Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx

Journal of Neuroscience Research

Volumn 85, Issue 14, 2007, Pages 3118-3126

  Song, Ning ^a   Jiang, Hong ^a   Wang, Jun ^a   Xie, Jun Xia ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

6 hydroxydopamine; Divalent metal transporter 1; Ferrous iron; Parkinson's disease; Substantia nigra

Indexed keywords

FERRIC AMMONIUM CITRATE; FERROUS ION; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; OXIDOPAMINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; INTRACELLULAR TRANSPORT; IRON TRANSPORT; MICROGLIA; NERVE CELL; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; CATION TRANSPORT PROTEINS; CELL COUNT; CELLS, CULTURED; FERRIC COMPOUNDS; FLUORESCEINS; GLIAL FIBRILLARY ACIDIC PROTEIN; IRON; IRON-REGULATORY PROTEINS; MICE; NEUROGLIA; NEURONS; OXIDOPAMINE; QUATERNARY AMMONIUM COMPOUNDS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TETRAZOLIUM SALTS; THIAZOLES; UP-REGULATION;

EID: 35848961208     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21430     Document Type: Article

References (43)

1. Berg D. 2006. In vivo detection of iron and neuromelanin by transcranial sonography - a new approach for early detection of substantia nigra damage. J Neural Transm 113:775-780.
2. Berg D, Hochstrasser H. 2006. Iron metabolism in parkinsonian syndromes. Mov Disord 9:1299-1310.
3. Blum D, Torch S, Nissou MF, Benabid AL, Verna JM. 2000. Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett 283:193-196.
4. Breuer W, Epsztejn S, Cabantchik ZI. 1995. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem 270:24209-24215.
5. Burdo JR, Menzies SL, Simpson IA, Garrick LM, Garrick MD, Dolan KG, Haile DJ, Beard JL, Connor JR. 2001. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res 66:1198-1207.
6. Conrad ME, Umbreit JN, Moore EG, Hainsworth LN, Porubcin M, Simovich MJ, Nakada MT, Dolan K, Garrick MD. 2000. Separate pathways for cellular uptake of ferric and ferrous iron. Am J Physiol Gastrointest Liver Physiol 279:G767-G774.
7. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M. 1998. In vitro studies of ferritin iron release and neurotoxicity. J Neurochem 70:2492-2499.
8. Eisenstein RS. 2000. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 20:627-662.
9. 125I- ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 60:2338-2341.
10. Fleming MD, Trenor CC, Su MA, Foernzler D, Beier DR, Dietrich WF, Andrews NC. 1997. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 16:383-386.
11. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC. 1998. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci U S A 95:1148-1153.
12. Gruenheid S, Canonne-Hergaux F, Gauthier S, Hackam DJ, Grinstein S, Gros P. 1999. The iron transport protein NRAMP2 is an integral membrane glycoprotein that colocalizes with transferrin in recycling endosomes. J Exp Med 189:831-841.
13. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:482-488.
14. Gunshin H, Allerson CR, Polycarpou-Schwarz M, Rofts A, Rogers JT, Kishi F, Hentze MW, Rouault TA, Andrews NC, Hediger MA. 2001. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett 509:309-316.
15. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S. 2006. 6-Hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem 281:5373-5382.
16. He Y, Lee T, Leong SK. 1999. Time-course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats. Neuroscience 91:579-585.
17. Huang E, Ong WY, Connor JR. 2004. Distribution of divalent metal transporter-1 in the monkey basal ganglia. Neuroscience 128:487-496.
18. Hubert N, Hentze MW. 2002. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci U S A 99:12345-12350.
19. Hulet SW, Heyliger SO, Powers S, Connor JR. 2000. Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J Neurosci Res 61:52-60.
20. Jiang H, Chen WF, Xie JX. 2001. Relationship between dopamine and iron contents in the brain of Parkinsonian rats. Acta Physiol Sin 53:334-338.
21. Jiang H, Xie JX, Qian ZM. 2003. The increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice. Acta Physiol Sin 55:571-576.
22. Jiang H, Luan Z, Wang J, Xie JX. 2006. Neuroprotective effects of iron chelator desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int 49:605-609.
23. Knutson M, Menzies S, Connor J, Wessling-Resnick M. 2004. Developmental, regional, and cellular expression of SFT/UbcH5A and DMT1 mRNA in brain. J Neurosci Res 76:633-641.
24. Lam-Yuk-Tseung S, Touret N, Grinstein S, Gros P. 2005. Carboxyl-terminus determinants of the iron transporter DMT1/SLC11A2 isoform II (-IRE/1B) mediate internalization from the plasma membrane into recycling endosomes. Biochemistry 44:12149-12159.
25. Moos T, Morgan EH. 2004. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 1012:14-26.
26. 2) control mammalian iron metabolism by different pathways. Mol Cell Biol 16:3781-3788.
27. Picard V, Govoni G, Jabado N, Gros P. 2000. Nramp 2 (DCT1/DMT1) expressed at the plasma membrane transports iron and other divalent cations into a calcein-accessible cytoplasmic pool. J Biol Chem 275:35738-35745.
28. Ponting CP. 2001. Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders? Hum Mol Genet 10:1853-1858.
29. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. 2003. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60:1761-1766.
30. Schipper HM, Vininsky R, Brull R, Small L, Brawer JR. 1998. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 152:188-196.
31. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. 2004. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46:254-263.
32. Suh YJ, Samuel D. 2003. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 278:27144-27148.
33. Tabuchi M, Yoshimori T, Yamaguchi K, Yoshida T, Kishi F. 2000. Human NRAMP2/DMT1, which mediates iron transport across endosomal membranes, is localized to late endosomes and lysosomes in HEp-2 cells. J Biol Chem 275:22220-22228.
34. Tandy S, Williams M, Leggett A, Lopez-Jimenez M, Dedes M, Ramesh B, Srai SK, Sharp P. 2000. Nramp2 expression is associated with pH-dependent iron uptake across the apical membrane of human intestinal Caco-2 cells. J Biol Chem 275:1023-1029.
35. Tenopoulou M, Doulias PT, Barbouti A, Brunk U, Galaris D. 2005. Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apoptosis. Biochem J 387:703-710.
36. Wang J, Jiang H, Xie JX. 2004. Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. Neurochem Res 29:2239-2243.
37. Wang X, Ghio AJ, Yang F, Dolan KG, Garrick MD, Piantadosi CA. 2002. Iron uptake and Nramp2/DMT1/DCT1 in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 282:L987-L995.
38. Williams K, Wilson MA, Bressler J. 2000. Regulation and developmental expression of the divalent metal-ion transporter in the rat brain. Cell Mol Biol 46:563-571.
39. Xie JX, Jiang H, Chen WF, Qian ZM. 2003. Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease. Exp Neurol 182:483-489.
40. Youdim MB, Stephenson G, Ben Shachar D. 2004. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306-325.
41. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. 2004. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863-873.
42. Zhang J, Stanton DM, Nguyen XV, Liu M, Zhang Z, Gash D, Bing G. 2005. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. Neuroscience 135:829-838.
43. Zoller H, Pietrangelo A, Vogel W, Weiss G. 1999. Duodenal metaltransporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet 353:2120-2123.